Match Document Document Title
9034377 Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax  
The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage...
9023388 Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof  
A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the...
9005943 Bone cell delivery device  
Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to...
8975273 Controlled release hydrocodone formulations  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8975271 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Controlled release hydrocodone formulations
 
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8969369 Abuse-resistant controlled-release opioid dosage form  
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if...
8962017 Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof  
A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the...
8956647 Pellet formulation for the treatment of the intestinal tract  
An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a...
8945616 Controlled release budesonide minitablets  
Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises...
8945615 Controlled release budesonide minitablets  
Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises...
8940328 Pellet formulation for the treatment of the intestinal tract  
An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a...
8932618 Biodegradable osmotic pump implant for drug delivery  
The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a...
8911778 Pellet formulation for the treatment of the intestinal tract  
An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a...
8906687 Blood brain barrier device  
Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to...
8901128 Pharmaceutical compositions of ranolazine  
A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s),...
8895065 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof  
There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts...
8889190 Extended-release topiramate capsules  
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein...
8871235 Compositions and their use in bone healing  
The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.
8871275 Extended release compositions comprising tolterodine  
The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate,...
8865210 Stable dosage formulations of imidazolylalkyl-pyridines  
Stable formulations of imidazolylalkyl-pyridines, including controlled-release formulations.
8858991 Delayed release oral pharmaceutical dosage forms comprising MGBG  
Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time...
8840923 Slow-release pharmaceutical formulation and process for its preparation  
Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release...
8822423 Affinity peptides toward infliximab  
We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable...
8821928 Controlled release pharmaceutical compositions for prolonged effect  
Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a...
8809271 Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device  
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable...
8802636 Combination therapy for treatment of sleep apnea  
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in...
8802139 Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient  
An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a...
8796226 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof  
Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a...
8784886 Coating capsules with active pharmaceutical ingredients  
Pharmaceutical compositions in unit dose form comprising capsules containing one or more first active pharmaceutical ingredient in a pharmaceutically acceptable vehicle, coated with one or more...
8771730 Carbidopa/Levodopa gastroretentive drug delivery  
A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more...
8758812 Composition for foodstuff for binding acetaldehyde  
This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s)...
8753678 Method and apparatus for forming delivery devices for oral intake of an agent  
Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more...
8753677 Ex vivo modifiable multiple medicament final dosage form  
Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a dosage portion having...
8748472 Stabilized formulations of CNS compounds  
Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.
8741343 Method of administering amantadine prior to a sleep period  
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine...
8741948 Oral antimicrobial pharmaceutical compositions  
The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious...
8722650 Extended-release minocycline dosage forms  
An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of...
8715723 Compositions and methods for delivery of amino-functional drugs  
Described are flexible, finite systems for the transdermal administration of scopolamine, comprising: (a) a polymer matrix comprising a polymer blend comprising (i) a non-functional acrylic-based...
8703186 Abuse-resistant oral dosage forms and method of use thereof  
An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but...
8703184 Delayed-release formulation for reducing the frequency of urination and method of use thereof  
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition...
8691203 Method comprising contacting tissue with a cross-linkable polyester prepolymer  
The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a...
8673350 Pharmaceutical formulations  
The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a...
8668932 Extended release venlafaxine formulation  
A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
8658207 Extended release tablet formulations of flibanserin and method for manufacturing the same  
The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in...
8652516 Doxycycline formulations, and methods of treating rosacea  
The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the...
8652487 Tolerogenic synthetic nanocarriers for inducing regulatory B cells  
Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune...
8652527 Extended-release topiramate capsules  
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein...
8652497 Pharmaceutical formulation containing irritant  
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating...
8642078 Coated formulations for tolterodine  
A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing...
8603520 Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors  
An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a...